AbbVie's immunology franchise, spearheaded by drugs Skyrizi and Rinvoq, is identified as a significant growth engine for the pharmaceutical giant. Sales from this segment now account for over half of the company's total revenue, highlighting its critical role in future performance.
AbbVie's Immunology Franchise Drives Growth with Skyrizi and Rinvoq
AbbVieImmunologySkyriziRinvoqPharmaceuticalsBiotech
